Effect of Combination Therapy on Visible/Non-Visible Symptoms, and Disease Burden Associated with Severe Rosacea: Results from A Post-Hoc Analysis of A Randomized Controlled Trial

Main Article Content

James Q Del Rosso
Mark Jackson
Sandra Johnson
Alison Harvey
Rajeev Chavda


Rosacea, disease burden, combination therapy


Abstract not available.


1. Steinhoff M, Schmelz M, Schauber J. Facial erythema of rosacea - aetiology, different pathophysiologies and treatment options. Acta Derm Venereol. 2016;96(5):579–586.

2. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus (ROSCO) 2019 panel. Br J Dermatol. August 2019. [Epub ahead of print]

3. National Rosacea Society Website. https://www.rosacea.org/rosacea-review/2010/winter/rosacea-now-estimated-to-affect-at-least-16-million-americans. Accessed November 21, 2019.

4. Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatolog Treat. June 2019. [Epub ahead of print]

5. Schaller M, Kemeny L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. May 2019. [Epub ahead of print]

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>